Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Association of Cytochrome-17 (MspA1) Gene Polymorphism with Risk of Gall Bladder Stones and Cancer in North India

  • Published : 2015.08.03
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Cholelithiasis is associated in 54%-98% of patients with carcinoma of the gallbladder, and a high incidence among females suggests a role of female hormones in the etiology of the disease. Cytochrome $P450C17{\alpha}$ (CYP-17) is a key enzyme involved in estrogen metabolism and polymorphisms in CYP-17 are associated with altered serum levels of estrogens. Thus, we investigated whether the CYP-17 MspA1 gene polymorphism might impact on risk of gall bladder cancers or gallstones, as well as to determine if this gene polymorphism might be linked with estrogen serum levels and lipid profile among the North Indian gall bladder cancer or gallstone patients. Materials and Methods: CYP-17 gene polymorphisms (MspA1) were genotyped with PCR-RFLP in cancer patients (n=96), stone patients (n=102), cancer + stone patients (n=52) and age/sex matched control subjects (n= 256). Lipid profile was estimated using a commercial kit and serum estrogen was measured using ELISA. Results: The majority of the patients in all groups were females. The lipid profile and estrogen level were significantly higher among the study as compared to control groups. The frequency of mutant allele A2 of CYP17 MspA1 gene polymorphism was higher among cancer (OR=5.13, 95% CI+3.10-8.51, p=0.0001), stone (OR=5.69, 95%CI=3.46-9.37, p=0.0001) and cancer + stone (OR=3.54, 95%CI=1.90-6.60, p=0.0001) when compared with the control group. However there was no significant association between genotypes of CYP17 MspA1 gene polymorphism and circulating serum level of estrogen and lipid profile. Conclusions: A higher frequency of mutant genotype A1A2 as well as mutant allele A2 of CYP-17 gene polymorphism is significantly associated with risk of gallbladder cancer and stones. Elevated levels of estrogen and an altered lipid profile can be used as predictors ofgall bladder stones and cancer in post menopausal females in India.

Keywords

References

  1. Admirand WH, Small DM (1968). The physicochemical basis of cholesterol gallstone formation in man. J Clin Invest, 47, 1043-52. https://doi.org/10.1172/JCI105794
  2. Ahlberg J (1979). Serum lipid levels and hyperlipoproteinaemia in gallstone patients. Acta Chir Scand, 145, 373-7.
  3. Ambrosone CB, Moysich KB, Furberg H, et al (2003). CYP17genetic polymorphism, breast cancer, and breast cancer risk factors. Breast Cancer Res, 5, 45-51.
  4. Bennion LJ, Grundy SM (1978). Risk factors for the development of cholelithiasis in man. N Engl J Med, 299, 1161-7. https://doi.org/10.1056/NEJM197811232992104
  5. Carey AH, Waterworth D, Patel K, et al (1994). Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism geneCYP17. Hum Mol Genet, 3, 1873-6. https://doi.org/10.1093/hmg/3.10.1873
  6. Carey MC (1992). Pathogenesis of gallstones. Recenti Prog Med, 83, 379-91.
  7. Castro FA, Koshiol J, Hsing AW, Devesa SS (2013). Biliary tract cancer incidence in the United States-Demographic and temporal variations by anatomic site. Int J Cancer, 133, 1664-72. https://doi.org/10.1002/ijc.28161
  8. Cavallini A, Messa C, Mangini V, et al (1987). Serum and bile lipids in young women with radiolucent gallstones. Am J Gastroenterol, 82, 1279-82.
  9. Cha BH, Bae JM (2014). Comparison of clinical outcomes of incidental and non-incidental gallbladder cancers: a singlecenter cross-sectional study. Asian Pac J Cancer Prev, 15, 1281-3. https://doi.org/10.7314/APJCP.2014.15.3.1281
  10. Channa NA, Fatehuddin Khand F, Allah Bux Ghanghrol AB, Soomro AM (2010). Quantitative analysis of serum lipid profile in gallstone patients and controls. Pak J Anal Environ Chem, 11, 59-65.
  11. Cirillo DJ, Wallace RB, Rodabough RJ, et al (2005). Effect of estrogen therapy on gallbladder disease. JAMA, 293, 330-9. https://doi.org/10.1001/jama.293.3.330
  12. Curado MP, Edwards B, Shin HR, et al (2007). Cancer incident in five continents, Vol IX. International agency for research cancer, Lyon, France, scientific publication, no.160.
  13. D.M. Small (1967). Physio-chemical studies of cholesterol gallstone formation. Gastroenterol, 52, 607-10.
  14. Diel AK (1980). Epidemiology of gall bladder cancer: a synthesis of recent data. J Nat Cancer Inst, 65, 1209-13.
  15. Diel AK (1983). Gallstone size and risk of gall bladder cancer. J Amer Med Ass, 250, 2323-6. https://doi.org/10.1001/jama.1983.03340170049027
  16. Dowling RH (2000). Review: pathogenesis of gallstones. Aliment Pharmacol Ther, 14, 39-47. https://doi.org/10.1046/j.1365-2036.2000.014s2039.x
  17. Dwivedi S, Madeshiya A, Singh D, Singh S, Krishna A (2013). Gall bladder cancer and some epidemiological factors: a cross sectional study. Biomedical Res, 24, 83-7.
  18. El-Ezzi AA, Zaidan WR, El-Saidi MA, et al (2014). Association of benign prostate hyperplasia with polymorphisms in VDR, CYP17, and SRD5A2 genes among lebanese men. Asian Pac J Cancer Prev, 15, 1255-62. https://doi.org/10.7314/APJCP.2014.15.3.1255
  19. Feigelson HS, Coetzee GA, Kolonel LN, Ross RK, Henderson BE (1997). A polymorphism in theCYP17gene increases the risk of breast cancer. Cancer Res, 57, 1063-5.
  20. Feigelson HS, Shames LS, Pike MC, et al (1998). Cytochrome P450c17a gene (CYP17) polymorphism is associated with serum oestrogen and progesterone concentration. Cancer Res, 58, 585-7.
  21. Friedewald WT, Levy RI, Fredrickson DS (1972). Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem, 18, 499-502.
  22. Gallus S, Negri E, Chatenoud L, et al C (2002). Postmenopausal hormonal therapy and gallbladder cancer risk. Int J Cancer, 99, 762-3. https://doi.org/10.1002/ijc.10411
  23. Haiman CA, Hankinson SE, Colditz GA, Hunter DJ, De Vivo I (2001). A polymorphism inCYP17and endometrial cancer risk. Cancer Res, 61, 3955-60.
  24. Haiman CA, Hankinson SE, Spiegelman D, et al (1999). The relationship between a polymorphism in CYP17with plasma hormone levels and breast cancer. Cancer Res, 59, 1015-20.
  25. Hart J, Modan B, Shanti M (1971). Cholelithiosis in the etiology of gall bladder neoplasm. Lancet, 1, 1151-3.
  26. Hewitt SC, Couse JF, Korach KS (2000). Estrogen receptor transcription and transactivation: estrogen receptor knockout mice-what their phenotypes reveal about mechanisms of estrogen action. Breast Cancer Res, 2, 345-52. https://doi.org/10.1186/bcr79
  27. Ho KJ (1977). Pathogenesis of human cholesterol cholelithiasis: a review and hypothesis. Ala J Med Sci, 14, 132-40.
  28. Hou L, Xu J, Gao YT, et al (2006). CYP17MspA1 polymorphism and risk of biliary tract cancers and gallstones: A populationbased study in Shanghai, China. Int J Cancer, 118, 2847-53. https://doi.org/10.1002/ijc.21708
  29. Hsing AW, Rashid A, Devesa SS, Fraumeni JF Jr (2006). Biliary tract cancer. in 'cancer epidemiology and prevention' , Eds Schottenfeld D, Fraumeni JFJr. Oxford University Press, New York, pp, 787-800.
  30. Juvonen T (1994). Pathogenesis of gallstones. Scand J Gastroenterol, 29, 577-82.
  31. Khan RA, Wahab S, Khan MA, Siddiqui S, Maheshwari V (2010). Advanced presentation of Gallbladder cancer: epidemioclinicopathological study to evaluate the risk factors and assess the outcome. J Pak Med Assoc, 60, 217-9.
  32. Khan ZR, Neugut AI, Ahsan H, Chabot JA (1999). Risk factors for biliary tract cancers. Am J Gastroenterol, 94, 149-52. https://doi.org/10.1111/j.1572-0241.1999.00786.x
  33. Kumar S, Masood N, Shaikh AJ, et al (2009). Clinical presentation and outcomes of patients with biliary malignancies: the Aga Khan University experience. Asian Pacific J Cancer Prev, 10, 463-6.
  34. Le MD, Henson D, Young H, Albores-Saavedra J (2011). Is gallbladder cancer decreasing in view of increasing laparoscopic cholecystectomy? Ann Hepatol, 10, 306-14.
  35. Miyoshi Y, Ando A, Ooka M, et al (2003). Association of CYP17genetic polymorphism with intra-tumoral estradiol concentrations but not withCYP17messenger RNA levels in breast cancer tissue. Cancer Lett, 195, 81-6. https://doi.org/10.1016/S0304-3835(02)00211-2
  36. Moerman CJ, Berns MP, Bueno de Mesquita HB, Runia S (1994). Reproductive history and cancer of the biliary tract in women. Int J Cancer, 57, 146-53. https://doi.org/10.1002/ijc.2910570203
  37. Mohr G, Kritz D, Barret E (1991). Plasma lipids and gallbladder disease. Am J Epidemiol, 134, 78-85.
  38. Nakamura S, Muro H, Suzuki S (1989). Estrogen and progesterone receptors in gallbladder cancer. Jpn J Surg, 19, 189-94. https://doi.org/10.1007/BF02471584
  39. National Cancer Registry Programme (2001). Consolidated reports of the population based cancer registries 1990-96, Indian council of medical research, New Delhi, India.
  40. Nedelcheva KV, Haraldsen EK, Anderson KB, et al (1999). CYP17 and breast cancer risk: the polymorphism in the 50 flanking area of the gene does not influence binding to Sp-1. Cancer Res, 59, 2825-8.
  41. Pavlidis TE, Pavlidis ET, Symeonidis NG, Psarras K, Sakantamis AK (2012). Current curative surgical management of gallbladder cancer: a brief review. J Curr Surg, 2, 81-3.
  42. Pettiti DB, Friedman GD, Klatsky AL (1981). Association of a history of gallbladder disease with a reduced concentration of high-density-lipoprotein cholesterol. N Engl J Med, 304, 1396-8. https://doi.org/10.1056/NEJM198106043042305
  43. Picado-Leonard J, Miller WL (1987), Cloning and sequence of the human gene for P450c17a (steroid 17a-hydroxylase/17, 20 lyase): similarity with the gene for P450c21. DNA, 6, 439-48. https://doi.org/10.1089/dna.1987.6.439
  44. Report on Carcinogens (2011). Twelfth edition. national toxicology program, department of health and human services, 184-7.
  45. Scallen TJ, Noland BJ, Gavey KL (1985). Sterol carrier protein 2 and fatty acid binding protein: separate and physiological function. J Bio Chem, 260, 4733-9.
  46. Service RF (1998). New role for estrogen in cancer? Science (Wash). 279, 631-3.
  47. Singh S, Dwivedi S, Chandra A, et al (2013). Serum estrogen level and lipid profile in Gall stone and Gallbladder cancer: a case control study. IJBR, 4, 415-20.
  48. Tada M, Yokosuka O, Omata M, Ohto M, Isono K (1990). Analysis of ras gene mutations in biliary and pancreatic tumors by polymerase chain reaction and direct sequencing. Cancer, 66, 930-5. https://doi.org/10.1002/1097-0142(19900901)66:5<930::AID-CNCR2820660519>3.0.CO;2-W
  49. Weber BL, Nathanson KL (2000). Low penetrance genes associated with increased risk for breast cancer. Eur J Cancer, 36, 1193-99. https://doi.org/10.1016/S0959-8049(00)00082-4
  50. Yadav SK, Mittal A, Sapkota K, Gupta S P, Sathian B (2013). Ability of biochemical parameters to distinguish between bile duct cancer and gall bladder stones-a case control study in a Tertiary care hospital of pokhara valley. Asian Pac J Cancer Prev, 14, 817-9. https://doi.org/10.7314/APJCP.2013.14.2.817
  51. Yilmaz MB, Pazarbasi A, Guzel AI, et al (2011). Association of serum sex steroid levels and bone mineral density with CYP17 and CYP19 gene polymorphisms in postmenopausal women in Turkey. Genetics Molecular Res, 10, 1999-2008. https://doi.org/10.4238/vol10-3gmr1204
  52. Zatonski WA, La Vecchia C, Przewozniak K, et al (1992). Risk factor for gall bladder cancer in a Polish case-control study. Int J Cancer, 51, 707-11. https://doi.org/10.1002/ijc.2910510508
  53. Zhang L-Q, Zhang X-D, Xu J, et al (2013). Potential therapeutic targets for the primary gallbladder carcinoma: estrogen receptors. Asian Pac J Cancer Prev, 14, 2185-90. https://doi.org/10.7314/APJCP.2013.14.4.2185
  54. Zuber MX, Simpson ER, Waterman MR (1986). Expression of bovine 17ahydroxylase cytochrome P-450 cDNA in nonsteroidogenic (COS 1) cells. Science, 234, 1258-61. https://doi.org/10.1126/science.3535074

Cited by

  1. Randomized-Control Screening Trials to Lower Gall Bladder Cancer Mortality in High Risk Populations vol.17, pp.4, 2016, https://doi.org/10.7314/APJCP.2016.17.4.2325